Mineralys Therapeutics Inc (NASDAQ:MLYS) price on Friday, June 13, fall -4.02% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $14.32.
A look at the stock’s price movement, the close in the last trading session was $14.92. Turning to its 52-week performance, $18.38 and $8.24 were the 52-week high and 52-week low respectively. Overall, MLYS moved -5.23% over the past month.
Mineralys Therapeutics Inc’s market cap currently stands at around $933.31 million, with investors looking forward to this quarter’s earnings report slated for in July.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend MLYS as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MLYS’s current price about -8.98% and -2.29% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.53, while 7-day volatility ratio is 1.47% and 2.61% in the 30-day chart. Further, Mineralys Therapeutics Inc (MLYS) has a beta value of -0.19, and an average true range (ATR) of 0.88. Analysts have given the company’s stock an average 52-week price target of $45, forecast between a low of $42 and high of $48. Looking at the price targets, the low is -193.3% off current price level while to achieve the yearly target high, price needs to move -235.2%. Nonetheless, investors will most likely welcome a -214.25% jump to $45 which is the analysts’ median price.
If we refocus on Mineralys Therapeutics Inc (NASDAQ:MLYS), historical trading data shows that trading volumes averaged 958.10K over the past 3 months. The company’s latest data on shares outstanding shows there are 64.88 million shares.
The 37.70% of Mineralys Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 65.21% of the company’s shares. Current price change has pushed the stock 16.33% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MLYS stock continues to rise going into the next quarter.
